Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL70049 | 0.98 | SCD (0.51) | SCDHTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5369367 | 0.87 | SLC6A2 (0.51) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C | |
| Hydrochloric Acid SCHEMBL4106087 | 0.86 | SLC6A2 (0.50) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C | |
| SCHEMBL1782182 | 0.83 | HTR2C (0.55) | SLC6A4HTR2CHTR2BNMT1 | |
| SCHEMBL83203 | 0.83 | SLC6A2 (0.62) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C | |
| Hydrochloric Acid SCHEMBL69817 | 0.82 | HTR1A (0.60) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C | |
| Hydrochloric Acid SCHEMBL10276656 | 0.82 | HTR2C (0.54) | SLC6A4HTR2CHTR2BNMT1 | |
| SCHEMBL473045 | 0.81 | HTR1A (0.51) | SCDHTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL1231225 | 0.81 | HTR2C (0.48) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C | |
| SCHEMBL1231616 | 0.81 | SLC6A2 (0.51) | HTR1ASLC6A2SLC6A3SLC6A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674416-A1 | PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION | NAGASAKI UNIVERSITY (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024181431-A1 | PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION | 国立大学法人 長崎大学 | 2024-09-06 | — | — | WO | disclosed |
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | disclosed |
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| US-8618287-B2 | Derivatives of triazines and uracils, their preparation and their application in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2013-12-31 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| WO-2011131593-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2011-10-27 | — | — | WO | disclosed |
| EP-2328886-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | Pierre Fabre Médicament (FR) | 2011-06-08 | — | — | EP | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | SCD 1/4885HTR1A 4153/4885SLC6A2 4356/4885 |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | UNG, TYMS, UMPS | SCD 3795/4885HTR1A 980/4885SLC6A2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.